Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer

Copyright © 2016. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 176(2017) vom: 01. März, Seite 63-70
1. Verfasser: Zirakzadeh, A Ali (VerfasserIn)
Weitere Verfasser: Kinn, Johan, Krantz, David, Rosenblatt, Robert, Winerdal, Malin E, Hu, Jin, Hartana, Ciputra Adijaya, Lundgren, Christian, Bergman, Emma Ahlén, Johansson, Markus, Holmström, Benny, Hansson, Johan, Sidikii, Alexander, Vasko, Janos, Marits, Per, Sherif, Amir, Winqvist, Ola
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't B cells CD86 Doxorubicin Immunology Neoadjuvant chemotherapy Urinary bladder cancer B7-2 Antigen Tumor Necrosis Factor-alpha mehr... Interleukin-10 130068-27-8 80168379AG
LEADER 01000naa a22002652 4500
001 NLM267486537
003 DE-627
005 20231224220803.0
007 cr uuu---uuuuu
008 231224s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2016.12.003  |2 doi 
028 5 2 |a pubmed24n0891.xml 
035 |a (DE-627)NLM267486537 
035 |a (NLM)28025135 
035 |a (PII)S1521-6616(16)30197-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zirakzadeh, A Ali  |e verfasserin  |4 aut 
245 1 0 |a Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 05.06.2017 
500 |a Date Revised 03.01.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2016. Published by Elsevier Inc. 
520 |a Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4+ T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-α. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a B cells 
650 4 |a CD86 
650 4 |a Doxorubicin 
650 4 |a Immunology 
650 4 |a Neoadjuvant chemotherapy 
650 4 |a Urinary bladder cancer 
650 7 |a B7-2 Antigen  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Doxorubicin  |2 NLM 
650 7 |a 80168379AG  |2 NLM 
700 1 |a Kinn, Johan  |e verfasserin  |4 aut 
700 1 |a Krantz, David  |e verfasserin  |4 aut 
700 1 |a Rosenblatt, Robert  |e verfasserin  |4 aut 
700 1 |a Winerdal, Malin E  |e verfasserin  |4 aut 
700 1 |a Hu, Jin  |e verfasserin  |4 aut 
700 1 |a Hartana, Ciputra Adijaya  |e verfasserin  |4 aut 
700 1 |a Lundgren, Christian  |e verfasserin  |4 aut 
700 1 |a Bergman, Emma Ahlén  |e verfasserin  |4 aut 
700 1 |a Johansson, Markus  |e verfasserin  |4 aut 
700 1 |a Holmström, Benny  |e verfasserin  |4 aut 
700 1 |a Hansson, Johan  |e verfasserin  |4 aut 
700 1 |a Sidikii, Alexander  |e verfasserin  |4 aut 
700 1 |a Vasko, Janos  |e verfasserin  |4 aut 
700 1 |a Marits, Per  |e verfasserin  |4 aut 
700 1 |a Sherif, Amir  |e verfasserin  |4 aut 
700 1 |a Winqvist, Ola  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 176(2017) vom: 01. März, Seite 63-70  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:176  |g year:2017  |g day:01  |g month:03  |g pages:63-70 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2016.12.003  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 176  |j 2017  |b 01  |c 03  |h 63-70